首页> 外文期刊>Advances in Therapy >Skin tolerability associated with transdermal drug delivery systems: an overview
【24h】

Skin tolerability associated with transdermal drug delivery systems: an overview

机译:与透皮给药系统相关的皮肤耐受性:概述

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

As transdermal patches become more widely prescribed, it is important that clinicians understand: (a) the common causes of skin reactions with these medications; (b) how to minimize these reactions; and (c) how to manage the signs and symptoms. Here we review published data for skin reactions with patch medications approved within the past decade. Overall, the most common application site signs and symptoms appear to be localized redness (erythema) or itching, sometimes accompanied by swelling (edema). Typically, these are mild to moderate in severity, transient in nature, and occur in 20% to 50% of patients. Most are localized to the area of application, and resolve spontaneously within several days following patch removal. Discontinuations due to these types of event are infrequent, ranging from 1.7% to 6.8% in the 6-month trials reviewed here. Based on expert opinion, the majority of these skin reactions would be a form of irritant contact dermatitis, with infrequent cases of allergic contact dermatitis. These types of reactions usually cause minimal pain or discomfort to the patient, and are unlikely to be of medical concern. Signs and symptoms of irritant contact dermatitis may be minimized by rotation of the application site, careful removal of the patch, and appropriate use of moisturizers and topical corticosteroids. In conclusion, the potential advantages of transdermal patches usually outweigh any additional skin issues; however, further research into treatment and management strategies is required.
机译:随着透皮贴剂的处方越来越广泛,临床医生必须了解:(a)这些药物引起皮肤反应的常见原因; (b)如何尽量减少这些反应; (c)如何管理体征和症状。在这里,我们回顾了过去十年中批准的贴剂引起的皮肤反应的公开数据。总的来说,最常见的应用部位迹象和症状似乎是局部发红(红斑)或瘙痒,有时伴有肿胀(水肿)。通常,这些疾病的严重程度为轻度至中度,本质上是暂时性的,发生在20%至50%的患者中。大多数都位于应用程序区域,并在去除补丁后几天内自发解决。由于这些类型的事件导致的停药现象很少见,在这里回顾的6个月试验中,停药的发生范围是1.7%至6.8%。根据专家的意见,这些皮肤反应中的大多数将是一种刺激性接触性皮炎,而过敏性接触性皮炎的病例很少。这些类型的反应通常对患者造成最小的疼痛或不适,并且不太可能引起医学上的关注。可通过旋转应用部位,小心地去除贴剂以及适当使用保湿剂和局部皮质类固醇激素来减少刺激性接触性皮炎的体征和症状。总之,透皮贴剂的潜在优势通常胜过任何其他皮肤问题。但是,需要进一步研究治疗和管理策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号